First Tracks Biotherapeutics Inc（TRAX）资讯与事件TRAXFirst Tracks Biotherapeutics Inc

First Tracks Anticipates Treating Four Indications by 2027

"First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases," said Daniel Faga, president and chief executive officer. "In celiac disease, FDA's Fast Track designation for ANB033 underscores both the urgency of the significant unmet need for patients and the potential of this program. We will report top-line data from Cohort 1 of the Phase 1b trial in Q4 2026, evaluating ANB033's potential to prevent gluten-induced mucosal injury. Cohort 2 of this study is enrolling patients with disease across a wide range of histologic and symptom severity at baseline with the goal of generating deeper insights into timing to mucosal healing and disease biology. We anticipate reporting these data in Q1 2027, followed by top-line data from our Phase 1b trial of ANB033 in eosinophilic esophagitis in Q3 2027."

Argenx Acquires Forte for $77/Share, H.C. Wainwright Bullish on First Tracks

After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday's share price and a total equity value of $2.2B, H.C. Wainwright said the firm views the Forte acquisition as "highly relevant" for First Tracks Biotherapeutics (TRAX). Forte's anti-CD122 antibody, FB102, is a direct competitor for First Tracks' ANB033 asset, which is in development for celiac disease and eosinophilic esophagitis, notes the analyst, who believes the rival acquisition news "bodes well for ANB033 and makes First Tracks a potential acquisition target, assuming Phase 1b CeD data are positive." The firm has a Buy rating on First Tracks and says it is evaluating its estimates and valuation assumptions based on today's news.

First Tracks Biotherapeutics Files to Sell 10.5M Shares of Common Stock

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders